Alejandro Sanz-Paris1,2, Javier Martinez-Trufero3, Julio Lambea-Sorrosal4, Raimon Milà-Villarroel5, Fernando Calvo-Gracia6. 1. Department of Endocrinology and Nutrition, Miguel Servet Hospital, 50009 Zaragoza, Spain. 2. Instituto de Investigación Sanitaria Aragón (IIS Aragon), 50009 Zaragoza, Spain. 3. Department of Medical Oncology, Miguel Servet Hospital, 50009 Zaragoza, Spain. 4. Department of Oncology, University Clinic Hospital, 50009 Zaragoza, Spain. 5. Group Research on Wellbeing (GRoW), Blanquerna School of Health Sciences-Universitat Ramon Llull, 08025 Barcelona, Spain. 6. Department of Endocrinology and Nutrition, University Clinic Hospital, 50009 Zaragoza, Spain.
Abstract
(1) Background: Nutritional status can influence the quality of life (QoL) of cancer patients. (2) Methods: This subanalysis evaluated the impact of an oral oligomeric enteral nutrition (OEN) protocol on the QoL of patients with oncology treatment-related diarrhea (OTRD) in a multicenter, observational, prospective study (DIAPOENO study). QoL was assessed with the Nottingham Health Profile (NHP) at baseline and after eight weeks of OEN treatment. (3) In the overall population, all the NHP categories significantly improved after eight weeks of OEN treatment: energy levels (p < 0.001), pain (p < 0.001), emotional reactions (p < 0.001), sleep (p < 0.001), social isolation (p = 0.023), and physical abilities (p = 0.001). QoL improvement was higher in patients with improved or maintained nutritional status and in those with improved consistency of stools with the OEN protocol. However, QoL did not significantly improve in patients with worse nutritional status and with worse or maintained stool consistency with the OEN protocol. QoL improved regardless of disease severity. Multivariate logistic regression analysis showed that weight change was significantly associated with improved QoL (OR 2.90-5.3), except for social isolation, in models unadjusted and adjusted to age, sex, oncology treatment, and stool consistency. (4) Conclusion: In this subanalysis, the OEN protocol was associated with improved QoL.
(1) Background: Nutritional status can influence the quality of life (QoL) of cancerpatients. (2) Methods: This subanalysis evaluated the impact of an oral oligomeric enteral nutrition (OEN) protocol on the QoL of patients with oncology treatment-related diarrhea (OTRD) in a multicenter, observational, prospective study (DIAPOENO study). QoL was assessed with the Nottingham Health Profile (NHP) at baseline and after eight weeks of OEN treatment. (3) In the overall population, all the NHP categories significantly improved after eight weeks of OEN treatment: energy levels (p < 0.001), pain (p < 0.001), emotional reactions (p < 0.001), sleep (p < 0.001), social isolation (p = 0.023), and physical abilities (p = 0.001). QoL improvement was higher in patients with improved or maintained nutritional status and in those with improved consistency of stools with the OEN protocol. However, QoL did not significantly improve in patients with worse nutritional status and with worse or maintained stool consistency with the OEN protocol. QoL improved regardless of disease severity. Multivariate logistic regression analysis showed that weight change was significantly associated with improved QoL (OR 2.90-5.3), except for social isolation, in models unadjusted and adjusted to age, sex, oncology treatment, and stool consistency. (4) Conclusion: In this subanalysis, the OEN protocol was associated with improved QoL.
Entities:
Keywords:
nutritional protocol; oligomeric enteral nutrition; oncology treatment-related diarrhea; quality of life
Authors: Jann Arends; Patrick Bachmann; Vickie Baracos; Nicole Barthelemy; Hartmut Bertz; Federico Bozzetti; Ken Fearon; Elisabeth Hütterer; Elizabeth Isenring; Stein Kaasa; Zeljko Krznaric; Barry Laird; Maria Larsson; Alessandro Laviano; Stefan Mühlebach; Maurizio Muscaritoli; Line Oldervoll; Paula Ravasco; Tora Solheim; Florian Strasser; Marian de van der Schueren; Jean-Charles Preiser Journal: Clin Nutr Date: 2016-08-06 Impact factor: 7.324
Authors: T Cederholm; R Barazzoni; P Austin; P Ballmer; G Biolo; S C Bischoff; C Compher; I Correia; T Higashiguchi; M Holst; G L Jensen; A Malone; M Muscaritoli; I Nyulasi; M Pirlich; E Rothenberg; K Schindler; S M Schneider; M A E de van der Schueren; C Sieber; L Valentini; J C Yu; A Van Gossum; P Singer Journal: Clin Nutr Date: 2016-09-14 Impact factor: 7.324
Authors: Jervoise Andreyev; Paul Ross; Clare Donnellan; Elaine Lennan; Pauline Leonard; Caroline Waters; Linda Wedlake; John Bridgewater; Rob Glynne-Jones; William Allum; Ian Chau; Richard Wilson; David Ferry Journal: Lancet Oncol Date: 2014-09 Impact factor: 41.316
Authors: Cristina Capatina; Constantinos Christodoulides; Alberto Fernandez; Simon Cudlip; Ashley B Grossman; John A H Wass; Niki Karavitaki Journal: Clin Endocrinol (Oxf) Date: 2013-01 Impact factor: 3.478
Authors: Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: G Bianchi; C Loguercio; D Sgarbi; R Abbiati; N Brunetti; T De Simone; M Zoli; G Marchesini Journal: Dig Liver Dis Date: 2003-01 Impact factor: 4.088
Authors: Linda S Elting; Catherine Cooksley; Mark Chambers; Scott B Cantor; Ellen Manzullo; Edward B Rubenstein Journal: Cancer Date: 2003-10-01 Impact factor: 6.860